title: The effects of levetiracetam on urinary 15f-2t-isoprostane levels in epileptic patients.
abstract: OBJECTIVE
  We aimed to investigate the effects of levetiracetam on oxidative stress which is one of the new antiepileptic drugs in epileptic patients.
  
  
  METHODS
  The study consisted of 21 patients with cryptogenic partial epilepsy. We determined the urinary 15F-2t-isoprostane levels of the 30 patients which is a marker of oxidative stress. Morning urine samples were collected from the patients before beginning LEV and after 3 months treatment. Of these patients 9 were excluded from the study that had seizure history in the last 1 month. Urinary levels of 15-F2t-isoprostane determined by ELISA initially and after 3 months treatment for each patient.
  
  
  RESULTS
  Mean age of the 21 patients was 29.6, of these 11 were females and 10 males. Mean urinary 15F-2t-isoprostane level of the patients was 876 ± 447 ng/mg Cr before the treatment of LEV. After 3 months treatment the mean 15F-2t-isoprostane level of the patients was 1560 ± 630. The patients had significantly higher levels of urinary 15F-2t-isoprostane when compared with initial levels (p = 0.025).
  
  
  CONCLUSIONS
  Our results showed the increase of urinary 15F-2t-isoprostane levels in epileptic patients whom were treated with LEV which may indicate that LEV induces the oxidative stress in epileptic patients.
authors.affiliation: Eskişehir Osmangazi University, Medical Faculty, Department of Anatomy, Eskisehir, Turkey.
authors.forename: Hilmi
authors.initials: H
authors.lastname: Ozden
authors.forename: Sibel Canbaz
authors.initials: SC
authors.lastname: Kabay
authors.forename: Aysun
authors.initials: A
authors.lastname: Toker
authors.forename: Mehmet Cengiz
authors.initials: MC
authors.lastname: Ustüner
authors.forename: Cansu
authors.initials: C
authors.lastname: Ozbayer
authors.forename: Derya
authors.initials: D
authors.lastname: Ustüner
authors.forename: Hasan Veysi
authors.initials: HV
authors.lastname: Günes
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000008:administration & dosage*; D015415:Biomarkers / Q000652:urine; D015237:Dinoprost / Q000031:analogs & derivatives; D004828:Epilepsies, Partial / Q000188:drug therapy / Q000378:metabolism; D004827:Epilepsy / Q000188:drug therapy* / Q000378:metabolism*; D005260:Female; D006801:Humans; D028421:Isoprostanes / Q000652:urine*; D000077287:Levetiracetam; D008297:Male; D018384:Oxidative Stress / Q000187:drug effects*; D010889:Piracetam / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D000927:Anticonvulsants; D015415:Biomarkers; D028421:Isoprostanes; C075750:8-epi-prostaglandin F2alpha; D000077287:Levetiracetam; D015237:Dinoprost; D010889:Piracetam